Terbinafine tablet is a synthetic derivative of allylamine with broad spectrum antifungal activity. With fungicidal or fungistatic activity against yeasts depending on the species; It is a fungicide against dermatophytes and dimorphic fungi certain low concentrations. The molecule is concentrated in skin, nails and hair when administered orally, reaching associated with fungicidal activity levels.

Terbinafine causes cell death in sensitive fungi by inhibiting squalene monooxygenase enzyme that is responsible for the synthesis of ergosterol, an essential component of the membrane of the fungus and the accumulation of its predecessor, squalene.

TERBINAFINE MK® is indicated as an antifungal.

It is recommended to use a tablet TERBINAFINE MK® a day (250 mg / day); or as prescribed. Clinical experience with this antimycotic administered orally to reports that has been used to treat skin infections, hair and nails I heal dermatophytes and yeasts caused by various species.

• Depending on the type of mycosis, literature recommends the following duration of treatment: Tinea pedis, two to six weeks. Tinea corporis and cruris, two to four weeks. cutaneous candidiasis, two to four weeks.

• scalp infections: tinea capitis, four weeks.

• Onychomycosis: six to twelve weeks. It has been observed that the fingernails respond faster. Hallux fingernail (foot) may require, in some cases, more than three months of treatment. Recurrence may occur with irregular use or stopping the medication. Complete resolution of the signs and symptoms of infection may not occur until several weeks after mycological control. The length of treatment varies according to the indication and severity of the infection.

• Absorption: Terbinafine has a bioavailability of 40% and 70% absorption with extensive first pass metabolism. With the oral administration of 250 mg, 2 hours maximum serum concentration of 1 mg / ml is obtained. Apparently the pharmacokinetics is not influenced by age. It is extensively metabolized in the liver and 70% of the dose is excreted renally, has not been able to determine active metabolites. The plasma clearance is reduced by 50% in patients with hepatic or renal impairment.

• Distribution: Terbinafine is widely distributed in the subcutaneous fatty tissue and skin; it binds to plasma proteins by more than 99%. Elimination half-life plasma elimination varies between 17 to 36 hours. The terminal half-life is about 200-400 hours due to the low rate of removal of tissues such as skin and adipose tissue.

Clinical experience regarding overdose with oral terbinafine is limited. Doses of up to 5 grams (20 times the daily therapeutic dose) were taken without inducing severe adverse reactions. Overdose symptoms included nausea, vomiting, abdominal pain, dizziness, rash, increased urinary frequency or headache.